Herpes simplex virus vaccines

Vaccine

Volumn 17, Issue 13-14, 1999, Pages 1681-1689

  Bernstein, David I ^a   Stanberry, Lawrence R ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE;

ACTIVE IMMUNIZATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HERPES SIMPLEX; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT INFECTION; VACCINE PRODUCTION; VIRUS INHIBITION;

ANIMALS; ANTIGENS, VIRAL; HUMANS; SIMPLEXVIRUS; VACCINES, ATTENUATED; VACCINES, DNA; VIRAL VACCINES; VIRION; VIRUS REPLICATION;

EID: 0344267652     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00434-4     Document Type: Conference Paper

References (90)

1. Stanberry LR, Jorgensen DM, Nahmias AJ. Herpes simplex viruses 1 and 2. In: Evans AS, Kaslow RA, editors. Viral infections of humans: epidemiology and control. 4th ed. New York: Plenum Medical Book Company, 1997. p. 419-54.
2. Whitley R.J., Kimberlin D.W., Roizman B. Herpes simplex viruses. Clin. Infect. Dis. 26:1998;541-553.
3. Patel R., Barton S.E. Antiviral chemotherapy in genital herpes simplex virus infections. Int. J. STD AIDS. 6:1995;320-328.
4. Fleming D.T., McQuillan G.M., Johnson R.E.et al. Herpes simplex virus type 2 in the US, 1976-1994. New Engl. J. Med. 337:1997;1105-1111.
5. Lipchutz B. Untersuchungen über die Atiologie der Krankheiten der Herpesgruppe. Arch. Dermatol. Syphilol. 136:1921;428.
6. Hall M.J., Katrak K. The quest for a herpes simplex virus vaccine: background and recent developments. Vaccine. 4:1986;138-150.
7. Milligan G.N., Bernstein D.I., Bourne N. T-lymphocytes are required for protection of the vaginal mucosa and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160:1998;6093-6100.
8. Bernstein D.I., Stanberry L.R., Harrison C.J., Kappes J.C., Myers M.G. Antibody response, recurrence patterns and subsequent HSV-2 reinfection following initial HSV-2 infection of guinea pigs: effect of acyclovir. J. Gen. Virol. 67:1986;1601-1612.
9. Stanberry L.R., Bernstein D.I., Kit S., Myers M.G. Genital reinfection after recovering from initial herpes simplex virus type 2 infection in guinea pigs. J. Infect. Dis. 153:1986;1055-1061.
10. Bernstein DI. Herpes simplex virus vaccines. In: Aly R, Beutner KR, Maibach HI, editors. Cutaneous infection and therapy. New York: Marcel Dekker, Inc., NY, 1997. p. 317-32.
11. Stanberry L.R. Evaluation of herpes simplex virus vaccine in animals: the guinea pig vaginal model. Rev. Infect. Dis. 11 (Suppl):1991;S920-S923.
12. Cunningham A.L., Merigan T.C. Leu3+ T-cells produce gamma-interferon in patients with recurrent herpes labialis. J. Immunol. 132:1984;197-202.
13. Koelle D.M., Posavad C.M., Barnum G.R., Johnson M.L., Frank J.M., Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T-lymphocytes. J. Clin. Invest. 101:1998;1500-1508.
14. Stanberry L.R. Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol. 3:1995;244-247.
15. Schiff B.L., Kern A.B. Multiple smallpox vaccinations in the treatment of recurrent herpes simplex. Postgrad. Med. 15:1954;32-36.
16. Foster P.D., Abshier A.B. Smallpox vaccine in treatment of recurrent herpes. Arch. Dermatol. Syphilol. 36:1937;294.
17. Bierman S.M. BCG immunoprophylaxis of recurrent herpes genitalis. Arch. Dermatol. 112:1976;1410.
18. Anderson F.D., Ushijima R.N., Larson C.L. Recurrent herpes genitalis: treatment with Mycobacterium bovis (BCG). Obstet. Gynaecol. 43:1974;797.
19. Lazar M.P. Vaccination for recurrent herpes simplex infection: initiation of a new disease site following the use of unmodified material containing the live virus. Arch. Dermatol. 73:1956;70-71.
20. Goldman L. Reactions of an autoinoculation for recurrent herpes simplex. Arch. Dermatol. 84:1961;1025-1026.
21. Woodman C.B.J., Buchan A., Fuller A.et al. Efficacy of vaccine Ac NFU1 (S-) MRC5 given after an initial clinical episode in the prevention of herpes genitalis. Br. J. Vener. Dis. 59:1983;311-313.
22. Kutinova L., Benda R., Kalos Z.et al. Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine. 6:1988;223-228.
23. Frank S.B. Formolized herpes virus therapy and neutralizing substance in herpes simplex. J. Invest. Dermatol. 1:1938;267-282.
24. Stanberry L.R. Herpes simplex virus vaccines. Sem. Pediatr. Infect. Dis. 2:1991;178-185.
25. Stanberry L.R., Burke R.L., Myers M.G. Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J. Infect. Dis. 157:1988;156-163.
26. Stanberry L.R., Harrison C.J., Bernstein D.I.et al. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy. Antiviral Res. 11:1989;203-214.
27. Ho R.J.Y., Burke R.L., Merigan T.C. Antigen-presenting liposomes are effective in the treatment of recurrent herpes simplex virus genitalis in guinea pigs. J. Virol. 63:1989;2951-2958.
28. Bernstein D.I., Harrison C.J., Tepe E.et al. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea pigs. Vaccine. 13:1995;72-76.
29. Myers M.G., Bernstein D.I., Harrison C.J.et al. Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs. Antiviral Res. 10:1988;83-88.
30. Burke R.L., Goldbeck C., Ng P., Stanberry L.R., Oh G., Vannest G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J. Infect. Dis. 170:1994;1110-1119.
31. Boursnell M.E., Entwisle C., Blakeley D.et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 175:1997;16-25.
32. Harrison CJ, Miller RL, Bernstein DI. Effect of S28463 as an adjuvant for an immunotherapeutic HSV glycoprotein D (gD) DNA vaccine: reduction of recurrent genital HSV disease in guinea pigs. In: Abstracts of the 36th ICAAC, New Orleans, LA, 1996, Abstract #H121.
33. Straus S.E., Corey L., Burke R.L.et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 343:1994;1460-1463.
34. Stanberry LR. The pathogenesis of herpes simplex virus infections In: Stanberry LR, editor. Genital and neonatal herpes. London: John Wiley and Sons, Ltd., 1996. p. 31-48.
35. Parr M.B., Parr E.L. Mucosal immuity to herpes simplex virus type 1 infection in the mouse vagina is impaired by in vivo depletion of T-lymphocytes. J. Virol. 72:1998;2677-2685.
36. Kuklin N.A., Daheshia M., Chun S., Rouse B.T. Role of mucosal immunity in herpes simplex virus infection. J. Immunol. 160:1998;5998-6003.
37. Gallichan W.S., Rosenthal K.L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177:1998;1155-1161.
38. Bernstein D.I., Harrison C.J., Jenski L., Myers M.G., Stanberry L.R. Cell mediated immunological responses and recurrent genital herpes in the guinea pig: effects of glycoprotein immunotherapy. J. Immunol. 146:1991;3571-3577.
39. Roizman B., Warren J., Thuning C.A.et al. Application of molecular genetics to the design of live herpes simplex virus vaccines. Dev. Biol. Stand. 52:1982;287-304.
40. Burke R.L. Contemporary approaches to vaccination against herpes simplex virus. Curr. Top. Microbiol. Immunol. 179:1992;137-158.
41. Stanberry LR. Subunit viral vaccines: therapeutic and prophylactic uses. In: Aurelian L, editor. herpesviruses, the immune system and Aids. Boston, MA: Kluwer Academic Publishers, 1991. p. 309-41.
42. Ghiasi H., Nesburn A.B., Wechsler S.L. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine. 14:1996;107-112.
43. Mertz G.J., Ashley R., Burke R.L.et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J. Infect. Dis. 161:1990;653-660.
44. Stanberry L.R., Bernstein D.I., Burke R.L.et al. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155:1987;914-920.
45. Sanchez-Pescador L., Burke R.L., Ott G.et al. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J. Immunol. 141:1988;1720-1727.
46. Berman P.W., Gregory T., Crase D.et al. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science. 227:1985;1490-1491.
47. Ghiasi H., Kaiwar R., Nesburn A.B., Slanina S., Wechsler S.L. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. J. Virol. 68:1994;2118-2126.
48. Watson R.J., Weis J.H., Salstrom J.S.et al. Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli. Science. 218:1982;381-384.
49. Pachl C., Burke R.L., Struve L.L.et al. Expression of cell-associated an secreted forms of herpes simplex virus type 1 glycoprotein B in mammalian cells. J. Virol. 61:1987;315-325.
50. Langenberg A.G., Burke R.L., Adair S.F., Sekulovich R., Tigges M., Dekker C.L., Corey L. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and immunogenicity. Ann. Int. Med. 122:1995;889-898.
51. Leroux-Roels G., Moreau E., Desombere I. et al. Persistence of humoral and cellular immune response and booster effect following vaccination either herpes simplex (gD2t) candidate vaccine with MPL. In: 34th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October, 1994.
52. Stanberry L.R., Bernstein D.I., Burke R.L., Pachl C., Myers M.G. Recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155:1987;914-920.
53. Burke R.L. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. Rev. Infect. Dis. 3:1991;S906-S911.
54. Stanberry L.R., Myers M.G., Stephanopoulos D.E.et al. Preinfection prophylaxis with herpes simplex virus immunogens: factors influencing efficacy. J. Gen. Virol. 70:1989;3177-3185.
55. Leroux-Roels G, Moreau E, Verhasselt B et al. Immunogenicity and reactogenicity of recombinant herpes simplex virus type-2 (HSV-2) glycoprotein D vaccine with monophosphoryl lipid A in HSV-seronegative and seropositive subjects. In: Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, LA, 1993. p. 64, #1209.
56. Stanberry LR, Bourne N, Bravo FJ, Slaoui M, Myers MG. Recombinant glycoprotein therapy of experimental recurrent genital herpes. In: Abstracts of the 31st ICAAC, 1991, Abstract #1118.
57. Keadle T.L., Laycock K.A., Miller J.K.et al. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. J. Infect. Dis. 176:1997;331-338.
58. Straus S.E., Wald A., Kost R.G.et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled trial. J. Infect. Dis. 176:1997;1129-1134.
59. Meignier B., Longnecker R., Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis. 158:1988;602-613.
60. Meignier B., Martin B., Whitley R.J.et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162:1990;313-321.
61. Cadoz M, Micoud M, Seigneurin JM et al. Phase I trial of R7020: a live attenuated recombinant herpes simplex virus (HSV) candidate vaccine. In: Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Anaheim, CA, 1992. p. 167, Abstract #341.
62. Whitley R.J., Kern E.R., Chatterjee S., Chou J., Roizman B. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J. Clin. Invest. 91:1993;2837-2843.
63. Valyi-Nagy T., Fareed M.U., O'Keefe J.S.et al. The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J. Gen. Virol. 75:1994;2059-2063.
64. Spivack J.G., Fareed M.U., Valyi-Nagy T.et al. Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model. J. Gen. Virol. 76:1995;321-332.
65. Spector F.C., Kern E.R., Palmer J.et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J. Infect. Dis. 177:1998;1143-1154.
66. Perng G.C., Thompson R.L., Sawtell N.M.et al. An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation. J. Virol. 69:1995;3033-3041.
67. Nguyen L.H., Knipe D.M., Finbert R.W. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J. Virol. 66:1992;7067-7072.
68. Farrell H.E., McLean C.S., Harley C.et al. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J. Virol. 68:1994;927-932.
69. Morrison L.A., Knipe D.M. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J. Virol. 68:1994;689-696.
70. Da Costa X.J., Bourne N., Stanberry L.R., Knipe D.M. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology. 232:1997;1-12.
71. Hickling JK, Chrisholm SE, Duncan IA et al. Immunogenicity of a disabled infectious single cycle HSV-2 vaccine in phase I clinical trials in HSV-2 seropositive and seronegative volunteers. In: Abstracts of the 8th International Congress on Infectious Diseases, Boston, MA, May 1998. p. 89, Abstract #22.008.
72. Roberts JSC, Uttridge JA, Hickling JK et al. Safety tolerability and viral containment of a disabled infectious single cycle HSV-2 vaccine evaluated in phase I clinical trials in HSV-2 seropositive and seronegative volunteers. In: Abstracts of the 8th International Congress on Infectious Diseases, Boston, MA, May 1998. p. 89, Abstract #22.009.
73. Cremer K.J., Mackett M., Wohlengerg C.et al. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science. 228:1985;737-740.
74. Cantin E.M., Eberle R., Baldick J.et al. Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal HSV-1 challenge. Proc. Natl. Acad. Sci. USA. 80:1987;7155-7159.
75. McDermott M.R., Graham F.L., Hanke T.et al. Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology. 169:1989;244-247.
76. Gallichan W.S., Johnson D.C., Graham F.L.et al. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J. Infect. Dis. 168:1993;622-629.
77. Heineman TC, Connelly BC, Bourne N, Stanberry LR, Cohen J. Immunization with recombinant varicella zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J. Virol. 1995;69:8109-13.
78. Manning W.C., Paliard X., Zhou S.et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J. Virol. 71:1997;7960-7962.
79. Chabalgoity J.A., Khan C.M., Nash A.A., Hormaeche C.E. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol. Microbiol. 19:1996;791-801.
80. Karem K.L., Bowen J., Kuklin N., Rouse B.T. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J. Gen. Virol. 78:1997;427-434.
81. Ulmer J.B., Donnelly J.J., Parker S.E.et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
82. Manicken E., Rouse R.J.D., Yu A., Wire W.S., Rouse B.T. Genetic immunization against herpes simplex virus. J. Immunol. 155:1995;259-265.
83. Bourne N., Milligan G.N., Schleiss M.R., Bernstein D.I., Stanberry L.R. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine. 14:1996;1230-1234.
84. Kriesel J.D., Spruance S.L., Daynes R.A., Araneo B.A. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease. J. Infect. Dis. 173:1996;536-541.
85. Pachuk C.J., Arnold R., Herold K., Ciccarelli R.B., Higgins T.J. Humoral and cellular immune responses to herpes simplex virus-2 glycoprotein D generated by facilitated DNA immunization of mice. Curr. Top. Microbiol. Immunol. 226:1998;79-89.
86. Hariharan M.J., Driver D.A., Townsend K.et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J. Virol. 72:1998;950-958.
87. McClements W.L., Armstrong M.E., Keys R.D., Liu M.A. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc. Natl. Acad. Sci. USA. 93:1996;11414-11420.
88. Bourne N., Stanberry L.R., Bernstein D.I., Lew D. DNA immunization against experimental genital herpes simplex virus infection. J. Infect. Dis. 173:1996;800-807.
89. Bernstein DI, Tepe ER, Mester JC, Arnold RL, Stanberry LR, Higgins TJ. Effects of DNA immunization formulated with bupivaccaine in murine and guinea pig models of genital herpes simplex virus. Vaccine, in press.
90. McClements W.L., Armstrong M.E., Keys R.D., Liu M.A. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine. 15:1997;857-860.